title: [Transarterial oily chemoembolization combined with interstitial laser thermotherapy for treatment of hepatocellular carcinoma].
abstract: OBJECTIVE
  To evaluate the therapeutic effects and adverse effects of transarterial oily chemoembolization combined with interstitial laser thermotherapy (TOCE+ILT) in the treatment of hepatocellular carcinoma.
  
  
  METHODS
  Totally 120 patients with hepatocellular carcinoma were randomized into two groups and received interventions with TOCE+ILT or TOCE combined with percutaneous ethanol injection (TOCE+PEI). The treatment was repeated when necessary until the tumor was completely ablated, after which the therapeutic effects were evaluated and the patients were the followed up for observing long-term clinical outcome.
  
  
  RESULTS
  Of the 120 patients enrolled in this observation, 105 were followed up for two years (54 in TOCE+ILT group and 51 in TOCE+PEI group). The complete tumor necrosis rate of TOCE+ILT group was significantly higher than that of the TOCE+PEI group (84.8% vs 73.9%,Chi(2)=4.405, P=0.036), and TOCE+ILT was associated with a significantly higher negative conversion rate of AFP positivity (77.8% vs 56.1%, Chi(2)=4.592, P=0.032). The 1-year survival rate were similar between two groups, but the 2-year survival rate was significantly higher in patients with TOCE+ILT (79.6% vs 60.8%, Chi(2)=4.477, P=0.034). The hepatic function was comparable between the two groups before treatment, and 1 week after treatment, the ALT level in patients undergoing TOCE+ILT was significantly lower than that in patients with TOCE+PEI (95.90-/+56.06 U/L vs 116.31-/+45.27 U/L, t=2.04, P=0.043). Post-embolization syndrome was observed in the patients in two groups, but no severe adverse events were found.
  
  
  CONCLUSIONS
  TOCE+ILT has good therapeutic effects and mild side effects in the treatment of hepatocellular carcinoma.
authors.affiliation: Department of Oncology and Interventional Therapy, Cancer Center, Guangdong Provincial People's Hospital, Guangzhou 510080, China.
authors.forename: Ze-jian
authors.initials: ZJ
authors.lastname: Zhou
authors.forename: Rong-de
authors.initials: RD
authors.lastname: Xu
authors.forename: Wei-ke
authors.initials: WK
authors.lastname: Li
authors.forename: Wen-xing
authors.initials: WX
authors.lastname: Zhuang
authors.forename: Li-gong
authors.initials: LG
authors.lastname: Lu
authors.forename: Pei-jian
authors.initials: PJ
authors.lastname: Shao
authors.forename: Xiao-ming
authors.initials: XM
authors.lastname: Chen
authors.forename: Peng-fei
authors.initials: PF
authors.lastname: Luo
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D006801:Humans; D006979:Hyperthermia, Induced; D007834:Lasers; D008113:Liver Neoplasms / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome